Show simple item record

dc.contributor.authorAggarwal, Charu
dc.contributor.authorRolfo, Christian D
dc.contributor.authorOxnard, Geoffrey R
dc.contributor.authorGray, Jhanelle E
dc.contributor.authorSholl, Lynette M
dc.contributor.authorGandara, David R
dc.date.accessioned2021-01-11T19:49:21Z
dc.date.available2021-01-11T19:49:21Z
dc.date.issued2020-09-11
dc.identifier.urihttp://hdl.handle.net/10713/14323
dc.description.abstractUpfront tumour genotyping is now considered an essential step in guiding treatment decision-making in the management of patients with advanced-stage non-small-cell lung cancer (NSCLC) in light of the ever-expanding toolbox of targeted therapies and immune-checkpoint inhibitors. However, genotyping of tumour biopsy samples is not feasible for all patients and, therefore, genomic analysis of circulating tumour DNA (ctDNA) has emerged as a compelling non-invasive option. Current guidelines universally recommend genotyping and support the use of ctDNA testing in certain settings, although they often omit the detail necessary for integrating these tests into clinical care on an individual basis. In this Perspective, we describe the rationale, promise and challenges associated with ctDNA-based NSCLC genotyping and suggest a framework for the implementation of these assays into routine clinical practice. We also offer considerations for the interpretation of ctDNA genotyping results, which, particularly when using next-generation sequencing panels, can be nuanced. Through the addition of this new approach to clinical practice, we propose that oncologists might finally be able to utilize effective genotyping in nearly all patients with advanced-stage NSCLC. © 2020, Springer Nature Limited.en_US
dc.description.urihttps://doi.org/10.1038/s41571-020-0423-xen_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofNature Reviews. Clinical Oncologyen_US
dc.subject.meshCarcinoma, Non-Small-Cell Lung--geneticsen_US
dc.subject.meshCirculating Tumor DNA--geneticsen_US
dc.subject.meshGenotyping Techniquesen_US
dc.titleStrategies for the successful implementation of plasma-based NSCLC genotyping in clinical practiceen_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.doi10.1038/s41571-020-0423-x
dc.identifier.pmid32918064
dc.source.volume18
dc.source.issue1
dc.source.beginpage56
dc.source.endpage62
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record